A pharmaceutical giant predicts a huge profit from hundreds of millions of booster dose orders, and annual revaccination.
Business is booming for laboratories and at least one vaccine manufacturer. Chinese Communist Party (CCP) virus booster shots are expected to rake in a healthy surplus, especially after significantly lower research and development costs.
“Billions more in profits are at stake for some vaccine makers as the United States moves toward dispensing COVID-19 booster shots to shore up Americans’s protection against the virus,” the Associated Press reported. “How much the manufacturers stand to gain depends on how big the rollout proves to be.”
Financial analysts predict Pfizer’s 2022 global sales could total $26 billion. Moderna’s profits for the same year stand to jump about 35 percent according to the newswire agency.
The U.S. Food and Drug Administration (FDA) has only approved Pfizer’s booster vaccine for Americans aged 65 and up as well as for high-risk Americans.
However, the third shot will arguably soon be available for all Americans and the rest of the world. This includes jabs produced by competitors Moderna and Johnson & Johnson.
Vaccine boosters have become an entirely new business unit, and laboratories have already begun to compete worldwide. They are negotiating with the various health authorities to secure their market share.
Great Britain recently announced plans to offer boosters to all people over 50 years-old and other vulnerable people. Experts claim the Pfizer injection is the best choice, even if patients were vaccinated with a different brand.
Pfizer expects CCP virus vaccination will become an annual event.
“It is because the virus has spread all over the world that we will continue seeing new variants that are coming out, and also we will have vaccines that will last at least a year,” CEO Albert Bourla said according to Breitbart. “I think the most likely scenario is annual revaccinations but we need to wait and see the data.”